Tobacco could be back in the good books after it was revealed the plant was being used to manufacture the potentially life-saving experimental drug fighting Ebola. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/smoking_out_ebola_with_plantibodies_1002303Schering-Plough is planning to slash its US sales workforce by 20% in a bid to compensate for falling prescriptions of its drugs. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/schering-plough_slashes_us_workforce_by_20_987819Takeda has forked out $800 million to acquire US-based gout specialist URL Pharma in its bid to expand in the states – however, some analysts have found the deal baffling. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/takeda_buys_gout_company_url_pharma_977500The US Food and Drug Administration’s Janet Woodcock is under investigation for an alleged conflict of interest involving two generic drugmakers and approval of their drugs. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/woodcock_investigated_for_conflict_of_interest_983825The Biotechnology Industry Organisation is asking the US Government for a financial stimulus for small biotech companies that are struggling during the credit crunch. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/biotech_asks_us_government_for_help_986188Sanofi-Aventis has created the third largest generics company in Europe after re-branding its generic operations under the name Zentiva. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/sanofi-aventis_re-brands_generics_business_as_zentiva_979313Apotex has been unsuccessful in its bid to secure the rights to market a generic version of Sanofi-Aventis’ blockbuster blood thinner Plavix (clopidogrel) in Canada. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/apotex_loses_canadian_plavix_patent_case_986434Genentech and OSI Pharmaceuticals have announced the combination treatment of Avastin (bevacizumab) with Tarceva (erlotinib) has not shown to improve survival in a Phase III study. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/avastintarceva_combo_does_not_improve_survival_986661Sun Pharma has bought Ranbaxy for $4 billion to create the world’s fifth-biggest generic drugmaker. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/sun_buys_ranbaxy_for_$4_billion_1001783As many as 84% of Americans blame the pharmaceutical industry for the country’s healthcare woes, a new survey has found. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/pharma_partly_to_blame_for_healthcare_woes_983672
